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The principle of treating-to-target has been successfully
applied to many diseases outside rheumatology and
more recently to rheumatoid arthritis. Identifying
appropriate therapeutic targets and pursuing these
systematically has led to improved care for patients with
these diseases and useful guidance for healthcare
providers and administrators. Thus, an initiative to
evaluate possible therapeutic targets and develop treat-
to-target guidance was believed to be highly appropriate
in the management of systemic lupus erythematosus
(SLE) patients as well. Specialists in rheumatology,
nephrology, dermatology, internal medicine and clinical
immunology, and a patient representative, contributed to
this initiative. The majority convened on three occasions
in 2012–2013. Twelve topics of critical importance were
identified and a systematic literature review was
performed. The results were condensed and reformulated
as recommendations, discussed, modified and voted
upon. The finalised bullet points were analysed for
degree of agreement among the task force. The Oxford
Centre level of evidence (LoE, corresponding to the
research questions) and grade of recommendation (GoR)
were determined for each recommendation. The 12
systematic literature searches and their summaries led to
11 recommendations. Prominent features of these
recommendations are targeting remission, preventing
damage and improving quality of life. LoE and GoR of
the recommendations were variable but agreement was
>0.9 in each case. An extensive research agenda was
identified, and four overarching principles were also
agreed upon. Treat-to-target-in-SLE (T2T/SLE)
recommendations were developed by a large task force
of multispecialty experts and a patient representative. It
is anticipated that ‘treating-to-target’ can and will be
applicable to the care of patients with SLE.
INTRODUCTION
Over the past 50 years, the therapeutic strategy for
some of the most common chronic diseases has
evolved from a symptom-based to a target-based
approach, under the influence of evidence that such
approaches yield superior outcomes. For example,
in the management of hypertension, targeting suit-
ably chosen values for systolic or diastolic blood
pressure yields long-term reductions in the risks for
cardiovascular diseases.1 Likewise, in the manage-
ment of diabetes, targeting specific values for
blood-glucose, measured directly or indirectly by
haemoglobin A1c, has resulted in major improve-
ments in long-term prognosis.2
In the rheumatic diseases, where symptomatol-
ogy is often the predominant concern on the
patient’s part, it is less intuitive to investigate tar-
geted approaches. Nonetheless, in the management
of rheumatoid arthritis (RA), several randomised
clinical trials provided evidence that such targeted
approaches yielded superior outcomes in terms of
clinical course, long-term damage and functional
status.3–5 As a result, treat-to-target recommenda-
tions were developed for RA,6 prompting further
investigations and cautious implementation of such
approaches. More recently, treat-to-target recom-
mendations for the spondyloarthropathies were
also published.7
Systemic lupus erythematosus (SLE) is a chronic
disease where treatment is typically long-term or
even life-long. The disease engenders significant
symptomatologies, which are often the principal
drivers of the patient’s medical need for interven-
tions, however, not all disease activity is perceptible
as characteristic symptoms. SLE is also associated
with the progressive accumulation of irreversible
organ damage, which has been shown to be a pre-
dictor of further damage, additional morbidity and
early mortality.8 Based on these considerations, it
was reasonable to ask the question if the principles
of treating-to-target could be applied to the man-
agement of SLE as well. An international task force
was gathered to investigate this question and for-
mulate recommendations aimed at improving the
management of SLE in clinical practice through
target-based approaches. The task force directed a
systematic literature review (SLR), which served as
the evidence base, and developed a set of overarch-
ing principles and recommendations for
treating-to-target in SLE.
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The process followed for deriving these recommendations was
based on the treat-to-target initiative in RA.6 The idea for this
project originated in informal discussion between some of the
authors, most notably RvV, MM, JS and MS. A T2T/SLE
working group was formed consisting of a patients’ representa-
tive and 14 medical specialists with expertise in the clinical
investigation and treatment of SLE as well as in the process of
developing consensus-based guidance documents (additionally,
authors RvV, MM, DI, KL and MS had a more practical role
and were internally referred to as the ‘steering committee’).
Financial support was requested and obtained from two com-
panies (specified under Disclosures), but in both cases this
support was unrestricted and intended to cover the actual costs
of having the meetings including transportation, housing if
needed, and meeting facilities. The sponsors had no role in
setting the agenda or selecting participants; no company repre-
sentatives were present at any of the meetings, and the compan-
ies had no role in the writing of the manuscript (including no
‘writing support’). The working group convened in May and
August 2012 to determine the major topics for which a SLR
was required through a nominal process. This process resulted
in some consensus on the general direction of recommendations
and the development of the first draft of provisional overarching
principles. Following these meetings and extensive electronic
deliberations, the agenda for the systematic literature search was
identified as consisting of 12 distinct topics. During the final
months of 2012, this literature search was performed by authors
GB and AL with continued interactions with, and support from,
authors RvV and MM. The PubMed database was searched
using index terms, and all English language human studies were
evaluated based on the title, abstract and/or full text. The results
of the literature search were graded for the level of evidence
(LoE) on a scale of 1–5, and the grade of the ensuing recom-
mendation (GoR) was determined on a scale from A (highest) to
D (lowest).9 10
On the basis of the SLR, provisional recommendations were
developed and were circulated through the entire working
group and extensively discussed electronically and modified
accordingly. Subsequently, a larger meeting took place in
January of 2013, at which a larger number of international
experts were present. This group, the T2T/SLE international
task force (all authors), consisted of rheumatologists, nephrolo-
gists, dermatologists, internists, a clinical immunologist and a
patients’ representative; and in addition to the larger numbers
of European experts, representation was achieved from most
regions of the world including North America, South America,
Southeast Asia, and Australia/Oceania. During this meeting, dis-
cussions took place in plenary and break-out sessions, and the
principles of Delphi technique were applied for achieving con-
sensus. The original 12 topics were slightly reorganised (based
on considerable overlap in the relevant literature) yielding 11
recommendations. After extensive discussion, revised statements
were drafted and voted upon. Greater than 80% consensus was
achieved for all but two of the revised statements. These two
statements were discussed further and additional inquiries and
clarifications on points of the literature, as well as details of
wording, were requested. The final vote was performed by
email following the face-to-face meeting, and yielded >80%
consensus for both statements. Likewise, extensive electronic
communications again took place resulting in small additional
clarifications of wording and removal of redundant material.
The finalised overarching principles and recommendations
were circulated to the entire task force, and the agreement
with each statement was voted upon by all members, on a scale
of 0–10, the highest value indicating the greatest level of
agreement.
RESULTS
The T2T/SLE working group identified 12 areas of key import-
ance to be investigated by a SLR. These areas are shown in table 1,
along with the number of articles retrieved by each PubMed
search. The Overarching Principles and Recommendations achiev-
ing consensus from the larger International Task Force are shown
in box 1 and are discussed in detail below.
Overarching principles
The task force considered that the central guiding principles
towards the treatment for SLE, anchored deeply in humanistic
traditions and the nature of medicine, were not suitable for a
literature-based review, but could be codified through broad dis-
cussion and consensus. Thus, these principles were not investi-
gated through an examination of published data but were
extensively debated, circulated and voted upon.
The management of SLE should be based on shared decisions
between the informed patient and her or his physician(s)
A key ingredient of the decision-making process in SLE is the
patient’s autonomy: (s)he must be central in the process and
actively involved. The physician would, in most instances, have
to be a specialist experienced in the management of SLE, and
should work as part of a team, using an interdisciplinary
approach. Each therapeutic decision should be individualised
and balanced.
Shared decision making is the conversation that happens
between a patient and their health professional to reach a
healthcare choice together. This conversation needs patients and
professionals to understand what is important to the other
person when choosing a treatment (NHS 2012, http://sdm.
rightcare.nhs.uk/about/shared-decision-making/).
Table 1 Topics selected for the systematic literature search
Topic Articles, n
Correlation between disease activity and outcomes (damage
accrual, mortality, QoL)
257
Low disease activity and remission as surrogates of therapeutic
success against outcomes
40
Benefits and harms of treating serologically active but clinically
quiescent disease
2
Validated definitions of flares of disease activity against outcomes 27
Is sustained remission or prevention of flares an achievable goal? 95
Correlation between chronic, irreversible organ damage and
mortality
74
Correlation between chronic, irreversible organ damage and QoL 49
Early vs late, and intensive vs less intensive control of disease
activity
48
‘Induction-maintenance’ vs ‘induction-only’ treatment strategy 4
Long-term benefits and harms of glucocorticoids regimes in chronic
maintenance treatment
61
Benefits and harms of anticoagulation regimens in patients with
antiphospholipid antibodies
12
Benefits and harms of adjunct therapies 50
van Vollenhoven RF, et al. Ann Rheum Dis 2014;73:958–967. doi:10.1136/annrheumdis-2013-205139 959
Recommendation
 on 20 A









is: first published as 10.1136/annrheum





Treatment of SLE should aim at ensuring long-term survival,
preventing organ damage and optimising health-related
quality-of-life, by controlling disease activity and minimising
comorbidities and drug toxicity
This principle emphasises that, rather than a single target for
treatment, the treatment of SLE entails a range of targets that all
must be taken into account. The task force discussed whether a
‘hierarchy of targets’ could be established. Although some ele-
ments were self-evident (eg, survival takes precedence over low-
ering glucocorticoids), the task force was unable to establish a
conclusive recommendation regarding a hierarchy of targets.
The management of SLE requires an understanding of its many
aspects and manifestations, which may have to be targeted in a
multidisciplinary manner
The task force wished to recognise the diversity of clinical
expressions of SLE and the ensuing need for healthcare provi-
ders to be cognisant and aware of the multifaceted nature of the
disease. Moreover, it is recognised that the nature of SLE itself
may make it necessary, in many patients’ cases, to have care
delivered by more than one type of healthcare provider. This
requires several specialist physicians working together in the
management of one patient or a constellation of medical and
paramedical healthcare providers and non-medical professionals
working as a team if required.
Patients with SLE need regular long-term monitoring and review
and/or adjustment of therapy
As in some other chronic diseases, therapy traditions exist
where only acute needs are addressed at times of a medical crisis
or when the patient seeks medical help. For SLE, this is felt to
be as inappropriate as it is for diabetes mellitus. SLE can cause
serious derangements at different organ levels that may not be
perceived by the patient until significant damage (renal failure
due to nephritis) or a life-threatening situation have developed
(neutropenia, thrombocytopenia). The treatment of SLE may
likewise engender such risks (immunosuppressives), in particu-
lar, if therapeutic agents are continued longer than really
needed, or at too high a dose causing serious long-term conse-
quences (glucocorticoids). For all these reasons, patients with
SLE should be monitored regularly and, specifically, their treat-
ment needs to be reviewed and adjusted at reasonable time
intervals.11 Additionally, treatment of SLE must be tailored to
the individual patient.
Recommendations
The treatment target of SLE should be remission of systemic
symptoms and organ manifestations or, where remission cannot
be reached, the lowest possible disease activity, measured by a
validated lupus activity index and/or by organ-specific markers
Epidemiological studies with long-term observation period
(beyond 5 years) have demonstrated that SLE disease activity,
assessed on a single occasion or longitudinally, correlates posi-
tively with adverse patient outcomes, such as accrual of irrevers-
ible organ damage (quantified by the Systemic Lupus
International Collaborating Clinics (SLICC)/American College
of Rheumatology SLICC Damage Index (SDI)12) and mortality
(see online supplementary table S1). These associations have
been shown for validated global SLE disease activity indices
including the SELENA-SLEDAI (average score >3.5 during past
visits has a HR 1.7 for damage accrual13), SLEDAI-2K (HR for
mortality 1.15 per 1 unit adjusted mean score14), SLAM-R (HR
for damage 1.15 per 1 unit15), and BILAG (HR for death 1.15
per 1 unit; HR for new organ damage 1.08 per 1 unit16).
Furthermore, moderate or severe organ-specific lupus activity,
especially from the haematological,17 18 neuropsychiatric19 20
Box 1 Treat-to-target in systemic lupus erythematosus: overarching principles and bullet points
▸ Overarching principle 1: The management of systemic lupus erythematosus (SLE) should be based on shared decisions between the
informed patient and her/his physician(s).
▸ Overarching principle 2: Treatment of SLE should aim at ensuring long-term survival, preventing organ damage, and optimising
health-related quality-of-life, by controlling disease activity and minimising comorbidities and drug toxicity.
▸ Overarching principle 3: The management of SLE requires an understanding of its many aspects and manifestations, which may have
to be targeted in a multidisciplinary manner.
▸ Overarching principle 4: Patients with SLE need regular long-term monitoring and review and/or adjustment of therapy.
Recommendations:
1. The treatment target of SLE should be remission of systemic symptoms and organ manifestations or, where remission cannot be
reached, the lowest possible disease activity, measured by a validated lupus activity index and/or by organ-specific markers.
2. Prevention of flares (especially severe flares) is a realistic target in SLE and should be a therapeutic goal.
3. It is not recommended that the treatment in clinically asymptomatic patients be escalated based solely on stable or persistent
serological activity.
4. Since damage predicts subsequent damage and death, prevention of damage accrual should be a major therapeutic goal in SLE.
5. Factors negatively influencing health-related quality of life (HRQOL), such as fatigue, pain and depression should be addressed, in
addition to control of disease activity and prevention of damage.
6. Early recognition and treatment of renal involvement in lupus patients is strongly recommended.
7. For lupus nephritis, following induction therapy, at least 3 years of immunosuppressive maintenance treatment is recommended to
optimise outcomes.
8. Lupus maintenance treatment should aim for the lowest glucocorticoid dosage needed to control disease, and if possible,
glucocorticoids should be withdrawn completely.
9. Prevention and treatment of antiphospholipid syndrome (APS)-related morbidity should be a therapeutic goal in SLE; therapeutic
recommendations do not differ from those in primary APS.
10. Irrespective of the use of other treatments, serious consideration should be given to the use of antimalarials.
11. Relevant therapies adjunctive to any immunomodulation should be considered to control comorbidity in SLE patients.
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and renal domains,21–23 is also linked to damage accrual and/or
mortality. In accordance with these findings, data from cohort
studies and the extended follow-up of controlled trials suggest
that attainment of low disease activity or remission predicts
favourable long-term patient outcomes.24 25 The evidence is
strongest for lupus nephritis,26–28 where achievement of com-
plete renal response (remission)—usually defined as stable/
improved renal function with low-grade proteinuria (<0.5–1 g/
24 h) plus/minus inactive urine sediment—after administration
of immunosuppressive treatment is associated with significantly
lower risk (likelihood ratio 0.1426) for progression to end-stage
renal disease (ESRD).
The task force considered whether to define ‘remission’ for
general or organ-specific SLE. It was recognised that no gener-
ally accepted definition exists, and that there is disagreement
among experts on whether the most appropriate definition of
remission would be one that reflects only clinical disease
aspects, one that includes clinical and serological aspects, or one
that includes both and also puts limits on the treatments that are
allowed when a patient is said to be in remission. An earlier
EULAR initiative failed to resolve the issue completely.11
Definitively defining remission was felt to be outside the scope
of the current T2T/SLE project, but the T2T/SLE task force is
planning further work in this area. It was noted that recently
the Asia-Pacific Lupus Collaboration developed a preliminary
definition for a Lupus Low Disease Activity State.29
It was also recognised that the concept of ‘organ-specific out-
comes’ may be applicable only to some, but not to other, SLE
manifestations.
This recommendation also implies that at least one validated
disease activity measure30 should be regularly monitored in
every SLE patient along with organ-specific markers.
Prevention of flares (especially severe flares) is a realistic target in
SLE, and should be a therapeutic goal
Patients with SLE tend to follow a highly variable course with
periods of quiescence alternating with flares of activity. In recent
therapeutic trials of general SLE,31–34 and depending on the
disease activity instrument that is used, 64–74% of patients may
experience some degree of disease exacerbation after initial
achievement of low disease activity. Severe SLE flares, which
typically mandate the use of moderate-to-high doses of gluco-
corticoids and/or initiation or intensification of immunosuppres-
sive treatment, are encountered in 17–38% of patients.31–34
Likewise, studies in lupus nephritis have shown that exacerba-
tions of renal disease occur in 38–65%, and severe renal flares
in 8–26% of patients who initially responded to immunosup-
pressive treatment.26 27 35–38 Accordingly, and in spite of the
heterogeneity in definitions and follow-up periods, data from
large observational and controlled studies suggest that 10–40%
of SLE patients can achieve long-lasting (beyond 1 year) states of
absence of flares and/or disease remission.24 25 32 33 37 39
A large number of studies have demonstrated that exacerba-
tions of SLE activity (especially severe exacerbations) may
adversely impact on long-term patient outcomes, suggesting that
prevention of flares may be an important therapeutic goal in
SLE. There is ample evidence that renal disease exacerbations,
particularly severe nephritic flares—characterised by significant
reduction in glomerular filtration rate, reactivation of urine sedi-
ment and increase in proteinuria—after initial response to
immunosuppressive treatment, carry an increased risk (HR
13.927; likelihood ratio 11.826) for development of irreversible
renal damage or death. Similar associations have been
demonstrated for neuropsychiatric40 41 and general SLE18 41–44
flare-ups.
Thus, the task force felt that the literature supported both ele-
ments: that flare prevention should be a therapeutic goal, and
that it is a realistic target. Of course ‘realistic’ does not mean that
it can be achieved in every patient, but it was felt that the above-
referenced studies on flare prevention have demonstrated suffi-
ciently clearly that there are interventions that can prevent at
least some flares with a reasonable balance to risks/side effects.
It is not recommended that the treatment in clinically
asymptomatic patients be escalated based solely on stable or
persistent serological activity
In a clinically asymptomatic SLE patient with increasing sero-
logical activity (increasing anti-double-stranded (ds) DNA titres
usually accompanied by decreasing serum complement concen-
trations), there is an increased risk for developing flare, includ-
ing severe flare and flare from the kidneys or other major
organs.45–53 Closer monitoring is therefore advised. However,
the predictive value of these tests is modest (ORs ranging 1.8–
3.248 52 53) and thus, in the individual patient, there may be a
notable discordance between serological findings and clinical
outcome. Nevertheless, two small controlled studies in clinically
stable SLE patients with rising anti-dsDNA titres showed that
patients who were randomised to receive glucocorticoids (start-
ing dose 30 mg/day prednisone, then gradually tapered off)
developed fewer severe flares compared to those who did not
(combined relative risk 0.74; 95% CI 0.60 to 0.91).54 55
However, this approach carries the risk of overtreating patients
with glucocorticoids (number needed to treat to prevent one
major flare=5), and therefore, the task force concluded that
clinically asymptomatic patients with stable or persistent sero-
logical activity should not receive treatment escalation solely on
account of the serological findings. This is also supported with
results from a large cohort. The investigators followed clinically
quiescent SLE patients with prolonged (at least 2 years) sero-
logical activity for up to 10 years and found that they accrued
less damage compared to other SLE patients.56 57 In these
patients, closer monitoring is advised for prompt identification
of clinical flare signs.
Since damage predicts subsequent damage and death, prevention
of damage accrual should be a major therapeutic goal in SLE
Several cohort studies with large numbers of patients have
demonstrated that accrual of irreversible organ damage in SLE
is a strong prognostic factor for subsequent damage accrual in
the same or other organs (HR 1.30 per 1 unit SDI15) and also
for increased mortality (HR 1.40 per 1 unit SDI58). These asso-
ciations have been shown for the total SDI score and for indi-
vidual SDI domains, especially the renal and neuropsychiatric
items.22 59–61 Additionally, these effects are irrespective of
whether the damage is accrued early (within the first 1–3 years)
or later during the disease course, and whether the damage can
be attributed directly to the disease, or is considered a conse-
quence of (long-term) treatment, or a concomitant disorder.
Thus, prevention of damage includes control of disease activity,
prevention of flares and avoiding drug toxicity. Damage is reli-
ably measured by the SDI.
Factors negatively influencing health-related quality of life (HRQoL),
such as fatigue, pain and depression should be addressed in
addition to control of disease activity and prevention of damage
HRQoL is compromised in SLE patients as a result of the
disease itself but frequently also due to the coexistence of
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aggravating factors, especially fatigue, pain and depression
(reviewed in62 63). Thus, cross-sectional studies have reported
weak inverse associations between HRQoL and measures of SLE
activity64–66 and damage64 65 67–69 (correlation coefficients typ-
ically in the range of −0.20 to −0.52). Similarly, longitudinal
changes in disease activity67 70 71 and damage71–73 correlate
weakly with respective changes in HRQoL, and therapeutic
trials have shown modest concordance between clinical response
to treatment and improvement in HRQoL.74–76 Therefore, opti-
mising HRQoL should be considered independently in treat-
ment decisions and disease management. Put in other words, it
is recommended that the targets referred to earlier (remission,
absence of flares, etc) are pursued, while at the same time also
aiming for improvements in the many other factors that could
adversely impact on HRQoL. The task force discussed whether
HRQoL should be an additional therapeutic target but it was
considered that all previously indicated targets contribute to
HRQoL so that this is implied. From the patient’s point of view,
the ultimate goal is to ‘survive and to survive well’. This also
extends to the importance of ensuring the patients’ social func-
tioning including fitness to work.
Early recognition and treatment of renal involvement in SLE
patients is strongly recommended
No controlled trials have compared an ‘early’ versus ‘late’ thera-
peutic strategy against hard outcomes in SLE. Nonetheless,
extrapolated evidence from observational and therapeutic
studies suggests that patients with active severe SLE manifesta-
tions may benefit from early recognition and management of
their disease. Evidence is stronger for lupus nephritis, where
delay in diagnosis (by kidney biopsy) and initiation of immuno-
suppressive treatment has been associated with increased risk
for renal relapses (RR 1.03 per 1-month delay77) and ESRD
(HR 4.2 for delay >6 months).78–83 Similarly, timely (within
2 weeks) recognition and management of lupus myelopathy cor-
relates with improved outcome.84 85 Although the evidence is
lacking, in the opinion of the panelist, the same principle may
apply to other severe SLE manifestations. As for the intensity of
immunosuppressive treatment, meta-analyses of randomised
controlled studies in SLE patients with severe inflammatory
renal and CNS involvement have shown that the combination of
glucocorticoids with immunosuppressive agents is more effica-
cious than glucocorticoids alone.86 87
For lupus nephritis, following induction therapy, at least 3 years
of immunosuppressive maintenance treatment is recommended to
optimise outcomes
In lupus nephritis, after initial immunosuppressive (induction)
treatment, which aims to induce remission by controlling
immunologic activity, a subsequent longer period of less inten-
sive (maintenance) treatment is required to consolidate remis-
sion and prevent relapses.27 88–90 Based on the results of
controlled trials and their extended follow-up,21 35 91 it is
recommended that the duration of maintenance treatment in
lupus nephritis should be at least 3 years. This is also supported
by observational studies showing that early (before 18–
24 months after achieving response) tapering or discontinuation
of immunosuppressive treatment is associated with increased
risk (RR 2.6) for renal flares.92 93 We note that these studies do
show that maintenance therapy leads to better results overall,
but they do not completely prove that this is true even for those
patients who are in complete remission following induction
therapy. We believe this could be studied in various clinical trial
datasets, and this specific question is, therefore, on the research
agenda. We also emphasise that, as is generally the case, this rec-
ommendation must be applied in a flexible manner to take into
account the patient’s individual characteristics.
Although there is lack of evidence, the principle of induction-
maintenance immunosuppressive treatment is followed by many
experts in the management of other severe SLE manifestations
as well.
SLE maintenance treatment should aim for the lowest
glucocorticoid dosage needed to control disease, and if possible,
glucocorticoids should be withdrawn completely
A larger number of cohort studies in SLE have demonstrated a
significant dose-related association between exposure to systemic
glucocorticoids and damage accrual (HR 1.05 per 1 mg,15 and
HR 1.50 for >6–12 mg94 average daily prednisone dose). Most
frequently afflicted are the musculoskeletal, cardiovascular, per-
ipheral vascular, ocular and metabolic domains, and the effects
seem to be irrespective of the route or formula of glucocorticoid
administration. In children with SLE, high cumulative doses of
glucocorticoids may also adversely impact on growth.95 The
task force debated whether there was a safe lower level of gluco-
corticoid dosing. While this question has been studied in other
diseases where no such safe lower level could be identified,96 97
there are no studies specifically addressing this issue in SLE.
Nonetheless, based on the available evidence and general
pharmacological considerations, the task force supported the
main recommendation to aim for the lowest glucocorticoid
dosage during maintenance treatment, and the comment to
withdraw glucocorticoids completely ‘if possible’.
Prevention and treatment of antiphospholipid syndrome-related
morbidity should be a therapeutic goal in SLE; therapeutic
recommendations do not differ from those in primary
antiphospholipid syndrome
Antiphospholipid syndrome (APS) is present in approximately
16% of SLE patients, it contributes to increased damage accrual
and has major medical consequences for the patient and her/his
medical needs.98–101 Thus, awareness of the increased risk of
APS in SLE patients should be high to ensure rapid detection.
Although there is no randomised evidence to guide primary
thromboprophylaxis in SLE patients with positive antiphospholi-
pid antibodies, two cohort studies have demonstrated reduced
risk for first thrombosis in patients who were treated with acetyl-
salicylic acid and/or hydroxychloroquine.100 102 In SLE patients
with APS and history of thrombotic events, two randomised con-
trolled trials found comparable efficacy of low-intensity (target
INR 2.1–3.0) versus high-intensity (target INR >3.0) anticoagu-
lation in preventing recurrent thrombosis.103 104 Conversely, two
cohort studies that included patients with moderate/high-risk
antiphospholipid profile and/or history of arterial thrombotic
events, suggested benefit of the high-intensity regimen.105 106
The task force felt that a common misconception might be
that APS should be treated differently when occurring in the
context of SLE. There is no evidence to suggest this, and this
fact by itself prompted the task force to include the ‘negative’
final statement in this recommendation. Thus, it is recom-
mended that prevention and management of APS-related mor-
bidity in SLE patients should be similar to that in primary APS
patients.
Irrespective of the use of other treatments, serious consideration
should be given to the use of antimalarials
In the context of SLE, the medication class of ‘antimalarials’
refers primarily to chloroquine and hydroxychloroquine, with
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the latter being the favoured option, where available. Data pri-
marily from non-randomised studies have suggested favourable
effects of antimalarials on various SLE outcomes,107 such as a
reduction of flares (relative risk 0.43 for major flares),108
improvement of skin manifestations,109 110 prevention of
damage accrual (HR 0.55),111 112 and possible reduction in
mortality risk (HR 0.14–0.62);113–115 accordingly, some task
force members felt that this therapeutic class should be consid-
ered in all SLE patients unless contraindicated. Others, however,
pointed out that, while the literature supports the effectiveness
of antimalarials per se, the same studies also make it clear that
these agents have modest effect sizes that are subject to possible
confounding bias and are not free of risks, and thus, favoured
more restrained wording. Irrespective of this, contraindications
to these medications should of course, be respected.
Hydroxychloroquine was favoured, where available, over
chloroquine owing to a better safety profile. The antimalarial
mepacrine/quinacrine is used in some countries for cutaneous
manifestations in SLE.
Relevant therapies adjunctive to any immunomodulation should
be considered to control comorbidity in SLE patients
This recommendation reflects on such therapeutic categories as
antihypertensives, lipid-lowering agents, antihyperglycemics,
antiplatelet/anticoagulants, immunisations, and bone-protecting
agents, all of which are supported by strong evidence in the
appropriate clinical setting. In SLE patients, the above men-
tioned treatments seem to be as safe and efficacious as in the
general population,116–120 although there are no controlled
studies to demonstrate benefit against damage accrual or mortal-
ity. By contrast, there is poor evidence to support the use of
additional adjunctive therapies or complementary medicines to
achieve the key therapeutic targets in the management of SLE.
Agreement among experts
Agreements with the recommendations were assessed on a 0–10
scale in a final round of electronic voting, and yielded excellent
values ranging from 9.03–9.87 (table 2).
Research agenda
The SLR and the ensuing deliberations highlighted that several
important issues related to the management of SLE remain
elusive and will require additional, well-designed studies to
resolve. Thus, the task force established a research agenda based
on these findings (box 2). It should be noted that it is by no
means exhaustive, as it only represents those topics that
emerged from the SLR and deliberations. Moreover, only such
topics were included as could reasonably be approached
through current research efforts.
DISCUSSION
The international task force on treating-to-target in SLE (T2T/
SLE) has developed a set of Overarching Principles and
Recommendations that are expected to be the first step in a long-
term process. These bullets are directed at experienced physicians
and are not meant to replace clinical judgment, knowledge
acquired in appropriate training and continuous medical educa-
tion, and experience acquired in the real-world care of patients
with SLE. Moreover, the treatment targets identified here, or the
measures used to ascertain them, may have to be adjusted in
accordance with patient preferences, comorbidities or risks.
There may, in some situations, be confusion about the word
‘target’. Certainly the word ‘target’ could be used to indicate a
molecule or cell type that can be targeted with a medication or
biologic, but in the context of this article ‘target’ does, of
course, not refer to such drug therapy targets but to the thera-
peutic goal we set for each individual patient.
For treatment-to-target to be successful, as in the case of
hypertension, diabetes, or RA, three principal ingredients need
to be in place: it must be possible to identify the appropriate
target and to measure whether it has been achieved, and appro-
priate interventions must be available to (attempt to) achieve the
target. In the case of SLE, each of these is, to some extent,
lacking. Thus, the identification of therapeutic targets in SLE
revealed that the evidence in support of some was variable, and
more concentrated efforts to define appropriate targets are still
needed. High-level evidence for the long-term effectiveness of a
targeted-treatment strategy in SLE is not yet available, and the
conduct of large prospective randomised trials of targeted
versus standard care of SLE are warranted. This will also bear
on the issue of measuring the target, and, as already indicated,
further work to define the important target of ‘remission’ is
being undertaken. Other appropriate targets may be defined in
future prospective trials, but the relevant analyses in this regard
of existing large datasets, such as those available from rando-
mised drug trials in SLE, could provide very important add-
itional support. The task force recommends that at least one
validated disease activity measure should be regularly moni-
tored. Examples include the BILAG, SLEDAI, ECLAM and
others. As there is no clear evidence for using one of them over
the other, for now, clinicians can choose the instrument that
best suits their clinical situation. Perhaps the weakest link in
T2T/SLE is the availability of therapeutic options that would
make it possible, in practice, to aim for certain targets. The
therapeutic armamentarium for SLE consists of a relatively small
number of agents in the therapeutic classes of glucocorticoids,
antimalarials, immunosuppressives and biologics. In the latter
category, only one agent (belimumab) is approved for use in
SLE, and one (rituximab) is used not infrequently ‘off-label’ in
refractory cases.121 122 Fortunately, several new agents of









I – – 9.48
II – – 9.90
III – – 9.42
IV – – 9.81
Recommendations
1 3 (SLE)/1* (LN) C (SLE)/A (LN) 9.52
2 2 (SLE)/1* (LN) B (SLE)/A (LN) 9.32
3 2 B 9.03
4 1* A 9.71
5 2 B 9.03
6 2 B 9.87
7 2 B 9.13
8 2 B 9.58
9 3† C 9.52
10 2 B 9.35
11 4, 5‡ C 9.55
*Based on large number of well-designed cohort studies with large effect size(s).
†Based on low-quality randomized controlled trials and non-randomized controlled
cohort studies.
‡Mechanism-based reasoning or non-SLE evidence.
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considerable interest are in development for the treatment of
SLE, raising expectations that it will soon be possible to aim for
therapeutic targets with greater confidence that they can be
achieved. Thus, we regard this work as a first proactive step
towards a future where many new agents for SLE will make it
imperative to use them in the best possible manner
Recognising that many female patients with SLE are of child-
bearing age, the task force considered it important to emphasise
that the application of the treat-to-target principles may be par-
ticularly challenging in the peripregnancy setting. The use of
various classes of medications that would otherwise be consid-
ered in the application of treat-to-target to the individual
patient might, in some instances, be inappropriate when the
wish to conceive raises greater concerns for the well-being of
the patient or their offspring.
In summary, treat-to-target-in-SLE (T2T/SLE) recommenda-
tions were developed by a large task force of multispecialty
experts and a patient representative. The level of the evidence
was variable, but overall sufficient to provide acceptable strength
for each of the individual recommendations, and agreement
among experts was excellent. Prominent features of these
recommendations are targeting remission, preventing damage,
and improving health-related quality of life. It is anticipated that
‘treating-to-target’ can and will be applicable to the care of
patients with SLE in the future.
Author affiliations
1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases,
Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden
2Rheumatology Unit, University of Pisa, Pisa, Italy
3Department of Internal Medicine, University of Crete, Heraklion, Greece
4Division of Medicine, UCL, Centre for Rheumatology Research, London, UK
5Department of Dermatology, University of Muenster, Muenster, Germany
6Department of Dermatology, Lupus Europe, Romford, UK
7Medical Faculty, Department of Internal Medicine III, Technical University of
Dresden, Dresden, Germany
8Department of Rheumatology and Clinical Immunology, University Medical Center
Groningen, University of Groningen, Groningen, The Netherlands
9Department of Medicne/Rheumatology-Clinical Immunology, University of Crete,
Heraklion, Greece
10Arc Epidemiology Unit, University of Manchester, Manchester, UK
11Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain
12Division of Clinical Epidemiology, McGill University, Montreal, Canada
13Service de Médicine Interne 2, Hôpital Pitié-Salpêtrière, Paris, France
14Department of Rheumatology and Immunology, University of Pecs, Pecs, Hungary
15Department of Rheumatology and Clinical Immunology, University Medical Center
Utrecht, The Netherlands, Utrecht, The Netherlands
16Department of Medicne/Rheumatology and Clinical Immunology, Charite University
Hospital, Berlin, Germany
17Rheumatology Research Group, Birmingham University Medical School,
Birmingham, West Midlands, UK
18Department of Internal Medicine, Medical University of Graz, Graz, Austria
19Department of Rheumatology, Université Catholique de Louvain, Bruxelles,
Belgium
20Department of Internal Medicine, Istanbul University, Istanbul, Turkey
21Department of Rheumatology—4242, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark
22Department of Medicine, Addenbrooke’s Hospital, Cambridge, UK
23Institute of Rheumatology, Warsaw, Poland
24Discipline of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de
Janeiro, Brazil
25Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le
Kremlin—Bicêtre, France
26Southern Clinical School, Monash University, Clayton, Victoria, Australia
27Rheumatology Department, University of Santo Tomas Hospital, Manila,
Philippines
28Med. Abteilung für Nephrologie und Dialyse, Wilhelminenspital, Wien, Austria
29Department of Rheumatology, University College London, London, UK
30National Institute for Rheumatic Diseases, Piestany, Slovakia
31Department of Rheumatology, Medical University of Vienna, Vienna, Austria
32Unidade Imunologia Clínica, Department of Medicine, Hospital Santo António,
Porto, Portugal
33Department of Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands
34Department of Rheumatology, Odense University Hospital, Odense, Denmark
35Department of Nephrology, Moscow State Medicine and Dentistry University,
Moscow, Russian Federation
36Lanarkshire Centre for, East Kilbride, UK
37Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf,
Germany
Funding Supported by unrestricted grants from GSK and UCB pharmas.
Box 2 Research agenda for some of the 11
recommendations
Recommendation 1
▸ Development of definition(s) of remission in systemic lupus
erythematosus (SLE)
▸ Further studies linking specific disease activity states to
long-term outcomes
▸ Definition of a minimal acceptable disease activity
▸ Longitudinal studies investigating the long-term outcomes of
targeted treatment in non-renal SLE
▸ Prospective randomised trial comparing targeted versus
standard treatment in SLE
Recommendation 2
▸ Development and/or refinement of flare definitions and flare
assessment tools
▸ Prospective trials, including active-treatment trials as well as
withdrawal trials, to assess prevention of flare
Recommendation 4
▸ A meta-analysis of the numerous observational studies
linking damage to mortality
▸ A study specifically demonstrating that damage prevention
leads to gains in health-related quality of life (HRQoL)
Recommendation 5
▸ Definition of a set of key patient-reported outcomes in SLE
▸ Studies of non-inflammatory factors influencing HR-QoL in
patients with SLE
▸ Studies of interventions targeting such factors
Recommendation 7
▸ Prospective studies to investigate early intensive therapy and
the principle of induction/maintenance in non-renal lupus
▸ Studies based on existing clinical trial datasets to determine
if the general rule that maintenance therapy leads to better
results is true even for those patients who are in complete
remission following induction therapy.
Recommendation 8
▸ Studies to determine if a ‘safe’ lower level of long-term
glucocorticoid exposure can be identified
▸ Studies on glucocorticoid withdrawal
Recommendation 9
▸ Therapeutic studies in SLE antiphospholipid syndrome with
immunosuppressives/immunomodulators
▸ Studies on the feasibility of discontinuing anticoagulant
therapy following immunomodulation to suppress the
production of antiphospholipid antibodies
Recommendation 10
▸ Studies to determine if hydroxychloroquine must be
recommended or not in every patient with lupus. For how
long? At what dosage? And with or without monitoring of
serum drug level?
Recommendation 11
▸ More studies on complementary interventions in SLE
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